Additionally, Recursion plans to present updated clinical data from the TUPELO trial during a webinar scheduled for December 8, 2025. This presentation will provide further insights into the safety ...

Chicago-based CRISPR technology company Syntax Bio says it has developed tech that automates the slow, manual process of generating functional cell types, which may usher in a new generation of cell ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...

The number of Gen Z college freshmen who are entering universities without high school math skills is skyrocketing — as SAT scores are plummeting, a stunning new report has found. Even more shocking: ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Dr. Berg teaches philosophy at the University of California, Irvine. Last spring, it became clear to me that over half the students in my large general education lecture course had used artificial ...

Should a country financially support its artists? That’s the question that Ireland sought to answer with a pilot program that ran between 2022 and 2025, during which the government provided 2,000 ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

In the era of vibe coding, when even professionals are pawning off their programming work on AI tools, Microsoft is throwing it all the way back to the language that launched a billion devices. On ...